Prevalence of the metabolic syndrome in a population with overweight and obesity;Prevalencia del síndrome metabólico en una población de pacientes con sobrepeso y obesidad

Endocrinologia y Nutricion

Volumn 52, Issue 8, 2005, Pages 391-398

  Soto, A ^a   Bellido, D ^a   Buno M ^a   Pertega S ^a   Martinez Olmos M ^b   Vidal, O ^a  

^a HOSPITAL JUAN CANALEJO   (Spain)

^b Hospital Mexoeiro   (Spain)

Author keywords

Definition of metabolic syndrome; Insulin resistance; Prevalence

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; EVALUATION; FEMALE; GLUCOSE ASSAY; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL EXPERT; MEDICAL SOCIETY; METABOLIC SYNDROME X; OBESITY; PREVALENCE; SEX DIFFERENCE; SPAIN; WORLD HEALTH ORGANIZATION;

EID: 28444461512     PISSN: 15750922     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1575-0922(05)71038-X     Document Type: Article

References (39)

1. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes. 1992;41:715-22.
2. Isomaa B, Almgren P, Tuomi T, Forse'n B, Lahti K, Nisse'n M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683-9.
3. Reaven GM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes. 1988;37:1595-607.
4. Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic síndrome. Am J Cardiol. 1999;83:25F-9F.
5. Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO Consultation. Geneva: Department of Non-communicable Disease Surveillance, World Health Organization; 1999.
6. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. Europan Group for Study of Insulin Resistance (EGIR). Diabet Med. 1999;16:442-3.
7. Expert Panel on Detection, Evaluation, and Treatment of High Blood cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood cholesterol in Adults: Adult Treatment Panel III. JAMA. 2001;285:2486-97.
8. American Collage of Endocrinology Task Force on the Insulin Resistance Síndrome. American Collage of Endocrinology Position Statement on the insulin resistance Syndrome. Endocr Pract. 2002;9:236-52.
9. Schmidt MI, Duncan BB, Watson RL, Sharrett AR, Brancati Fl, Heiss G. A metabolic síndrome in whites and African-Americans: the Atherosclerosis Risk in Communities Baseline Suty. Diabetes Care. 1996;19:414-8.
10. Liese AD, Mayer-Davis EJ, Troler HA, Davis CE, Keil U, Scmidt MI, et al. Familial components of the multiple metabolic syndrome: the ARIC study. Diabetologia. 1997;40:963-70.
11. Alvarez León EE, Ribas Barba L, Serra Majem L. Prevalencia del síndrome metabólico en la población de las Islas Canarias. Med Clin (Barc). 2003;120:172-4.
12. Hernández A, Riera C, Solá E, Oliver MJ, Martínez ML, Morillas C, et al. Prevalencia del síndrome metabólico entre pacientes con cardiopatía isquémica. Med Clin (Barc). 2003;121:204-8.
13. Ascaso JF, Romero P, Real JT, Lorente RI, Martínez-Valls J, Carmena R. Abdominal obesity, insulin resistance, and metabolic syndrome in a southern European population. Eur J Intern Med. 2003;14:101-6.
14. Álvarez Cosmea A, López Fernández V, Suárez García S, Arias García T, Prieto Díaz MA, Díaz González L. Diferencias en la prevalencia del síndrome metabólico según las definiciones del ATP III y la OMS. Med Clin (Barc). 2005;124:368-70.
15. Foz M, Barbany M, Remesar X, Carrillo M, Aranceta J, García-Luna PP, et al. Consenso SEEDO'2000 para la evaluación del sobrepeso y la obesidad y el establecimiento de criterios de intervención terapéutica. Sociedad Española para el Estudio de la Obesidad (SEEDO). Med Clin (Barc). 2000;115:587-97.
16. Sociedad Española para el Estudio de la Obesidad. Consenso español 1996 para la evaluación de la obesidad y para la realización de estudios epidemiológicos. Med Clin (Barc). 1996;107:782-7.
17. Trinder P. Enzymatic colorimetric method for glucose determination. Ann Clin Biochem. 1969;6:24-7.
18. Berson S, Yellow RS. Quantitative aspects of the reaction between insulin and insulin-binding antibody. J Clin Invest. 1959;38:1996-2016.
19. Allain CC, Poon LS, Chan CSG, Richmod W, PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1979;20:470-5.
20. Ter HF, Baarscheer T, Fiolet JWT. Influence of free glycerol on enzymatic of triglycerides. Clin Chem. 1984;30:1102-3.
21. Radziuk J. Insulin sensitivity and its measurement: structural commonalities among the methods. J Clin Endocrinol Metab. 2000;85:4426-33.
22. Matthews DR, Hosker JP, Rudenski AS, Taylor BA, Teacher DF, Turner RC. Homeostasis model assessment: insulin resistance and B cell function from fasting plasma glucose and insulin concentration in man. Diabetologia. 1985;28:412-9.
23. American Diabetes Association Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2005;28 Suppl 1:S37-S42.
24. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C; American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109:433-8.
25. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among u.s. Adults. Diabetes Care. 2004;27:2444-9.
26. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K; DECODE Study Group. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med. 2004;164:1066-76.
27. Robbins DC, Andersen I, Bowsher R, Chance R, Dinesen B, Frank B, et al. Report of the American Diabetes Association's task force on standardization of the insulin assay. Diabetes. 1996;45:242-56.
28. Cameron AJ, Welborn TA, Zimmet PZ, Dunstan DW, Owen N, Salmon J, et al. Overweight and obesity in Australia: the 1999-2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab) Med J Aust. 2003;178:427-32.
29. Cameron AJ, Shaw JE, Zimmet PZ, Chitson P, Alberti KGGM, Toumiletho J. Comparison of WHO and NCEP metabolic syndrome definitions over 5 years in Mauritius. Diabetologia. 2003;46:A3068.
30. Anand SS, Yi Q, Gerstein H, Lonn E, Jacobs Ruby, Vuksan V, et al. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation. 2003;108:420-5.
31. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2003;163:427-36.
32. Grundy SM, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA; American Heart Association; National Heart, Lung, and Blood Institute; American Diabetes Association. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation. 2004;109:551-6.
33. Balkau B, Vernay M, Mhamdi L, Novak M, Arondel D, Vol S, et al. The incidente and persistente of the NCEP metabolic syndrome. The French D.E.S.I.R. study. Diabet Metab. 2003;29:526-32.
34. Palaniappan L, Carnethon MR, Wang Y, Hanley AJ, Fortmann SP, Haffner SM, Wagenknecht L; Insulin Resistance Atherosclerosis Study. Predictors of the incident metabolic syndrome in adults: the Insulin Resistance Atherosclerosis Study. Diabetes Care. 2004;27:788-93.
35. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere MA, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000;23:57-63.
36. Ascaso JF, Merchante A, Lorente RI, Real JT, Martínez-Valls J, Carmena R. A study of insulin resistance, using the minimal model, in non-diabetic familial combined hyperlipidemic patients. Metabolism. 1998;478:508-13.
37. Eschwège E, Richard JL, Thibult N, Ducimetière P, Warnet JM, Claude JR, et al. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels. The Paris Prospective Study, ten year later. Horm Metab Res Suppl. 1985;15:41-6.
38. Haffner SM, González C, Miettinen H, Kennedy E, Stern MP. A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes Care. 1996;19:1138-41.
39. Kashiwabara H, Inaba M, Maruno Y, Morita T, Awata T, Negishi K, et al. Insulin levels during fasting and the glucose tolerance test and HOMA's index predict subsequent development of hypertension. J Hypertens. 2000;18:83-8.